RXRX RECURSION PHARMACEUTICALS, INC.
Nasdaq · SEC CIK 1601830 · EDGAR
- Bought, last 12 months
- $0 0 purchases by 0 insiders
- Sold, last 12 months
- $8.93M 36 sales by 5 insiders
- Filings on record
- 457 since 2021-07-06, latest 2026-09-16 17:52
BoughtSold
Most active insiders, 12 months
| Insider | Title | Bought | Sold |
|---|---|---|---|
| Borgeson Blake | Dir | — | $4.10M |
| Gibson Christopher | Dir | — | $3.84M |
| Khan Najat | Chief R, D Commercial Off, Dir | — | $806.7K |
| Taylor Ben R | CFO | — | $157.7K |
| Bumpus Namandje | Dir | — | $28.1K |
| Michor Franziska | Dir | — | — |
| Hallett David | CSO | — | — |
| Dar Zavain | Dir | — | — |
| Li Dean Y | Dir | — | — |
| Sun Elaine D | Dir | — | — |
Transactions 743
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-01-29 | 2024-01-25 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 422.6K | +2% | +$8,480 |
| D | 2024-01-29 | 2024-01-25 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $10.35 | -8,000 | 414.5K | -2% | -$82.8K |
| 2024-01-25 | 2024-01-23 | RXRX | Borgeson Blake | Dir | S - Sale | $10.58 | -20.1K | 7.32M | -0.3% | -$212.2K | |
| D | 2024-01-18 | 2024-01-16 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 154.7K | +13% | +$40.0K |
| D | 2024-01-18 | 2024-01-16 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $10.93 | -18.0K | 136.7K | -12% | -$196.7K |
| DM | 2024-01-18 | 2024-01-16+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 1.01M | +8% | +$166.5K |
| DM | 2024-01-18 | 2024-01-16+ | RXRX | Secora Michael | CFO | S - Sale+OE | $10.35 | -50.0K | 981.0K | -5% | -$517.5K |
| M | 2024-01-11 | 2024-01-09 | RXRX | Borgeson Blake | Dir | S - Sale | $13.62 | -20.1K | 7.36M | -0.3% | -$273.2K |
| MI | 2024-01-11 | 2024-01-09 | RXRX | Li Dean Y | Dir | S - Sale | $13.66 | -29.0K | 422.0K | -6% | -$396.2K |
| DMI | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 4,000 | New | $0 |
| DMI | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.51 | -25.0K | 0 | -100% | -$237.7K |
| D | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 801.3K | +1% | $0 |
| D | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 791.3K | -1% | $0 |
| D | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $9.49 | -30.9K | 791.7K | -4% | -$292.8K |
| D | 2024-01-05 | 2024-01-03 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 822.6K | +4% | +$77.5K |
| 2024-01-04 | 2024-01-02 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,203 | 1.33M | +0.1% | $0 | |
| 2024-01-04 | 2024-01-02 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +1,900 | 58.1K | +3% | $0 | |
| 2024-01-04 | 2024-01-02 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,393 | 55.2K | +3% | $0 | |
| D | 2024-01-02 | 2023-12-28 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $10.58 | -8,000 | 414.5K | -2% | -$84.6K |
| D | 2024-01-02 | 2023-12-28 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 422.5K | +2% | +$8,480 |
| 2023-12-28 | 2023-12-26 | RXRX | Borgeson Blake | Dir | S - Sale | $10.63 | -20.1K | 7.36M | -0.3% | -$213.2K | |
| D | 2023-12-19 | 2023-12-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $9.60 | -18.0K | 136.7K | -12% | -$172.8K |
| D | 2023-12-19 | 2023-12-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 154.7K | +13% | +$40.0K |
| 2023-12-18 | 2023-12-14 | RXRX | Dar Zavain | Dir | S - Sale | $9.00 | -20.1K | 53.8K | -27% | -$181.3K | |
| DM | 2023-12-14 | 2023-12-12+ | RXRX | Secora Michael | CFO | S - Sale+OE | $7.49 | -50.0K | 943.5K | -5% | -$374.5K |
| DM | 2023-12-14 | 2023-12-12+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 981.0K | +8% | +$166.5K |
| 2023-12-14 | 2023-12-12 | RXRX | Borgeson Blake | Dir | S - Sale | $7.40 | -11.4K | 7.38M | -0.2% | -$84.7K | |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 851.2K | +4% | +$77.5K |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 819.9K | -1% | $0 |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.49 | -59.8K | 791.3K | -7% | -$448.1K |
| D | 2023-12-08 | 2023-12-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 829.9K | +1% | $0 |
| 2023-11-30 | 2023-11-28 | RXRX | Borgeson Blake | Dir | S - Sale | $6.72 | -11.4K | 7.40M | -0.2% | -$76.9K | |
| D | 2023-11-17 | 2023-11-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 158.4K | +13% | +$40.0K |
| D | 2023-11-17 | 2023-11-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $6.51 | -18.0K | 140.4K | -11% | -$117.2K |
| D | 2023-11-17 | 2023-11-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $7.18 | -3,603 | 136.7K | -3% | -$25.9K |
| D | 2023-11-17 | 2023-11-10 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 846.8K | +1% | $0 |
| D | 2023-11-17 | 2023-11-10 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 836.8K | -1% | $0 |
| D | 2023-11-17 | 2023-11-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $7.18 | -16.9K | 819.9K | -2% | -$121.4K |
| D | 2023-11-17 | 2023-11-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $7.18 | -5,378 | 413.4K | -1% | -$38.6K |
| D | 2023-11-17 | 2023-11-16 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $6.76 | -3,000 | 413.4K | -0.7% | -$20.3K |
| D | 2023-11-17 | 2023-11-16 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 416.4K | +0.7% | +$3,180 |
| DM | 2023-11-16 | 2023-11-14+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 963.2K | +8% | +$166.5K |
| DM | 2023-11-16 | 2023-11-14+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.82 | -50.0K | 938.2K | -5% | -$341.0K |
| D | 2023-11-16 | 2023-11-15 | RXRX | Secora Michael | CFO | F - Tax | $7.18 | -7,172 | 931.0K | -0.8% | -$51.5K |
| 2023-11-16 | 2023-11-14 | RXRX | Borgeson Blake | Dir | S - Sale | $6.32 | -8,885 | 7.41M | -0.1% | -$56.2K | |
| D | 2023-11-03 | 2023-11-01 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 874.0K | +4% | +$77.5K |
| D | 2023-11-03 | 2023-11-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $5.20 | -37.2K | 836.8K | -4% | -$193.3K |
| DMI | 2023-11-03 | 2023-11-01 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| DMI | 2023-11-03 | 2023-11-01 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $5.12 | -25.0K | 0 | -100% | -$127.9K |
| 2023-11-02 | 2023-10-31 | RXRX | Borgeson Blake | Dir | S - Sale | $5.27 | -8,885 | 7.42M | -0.1% | -$46.8K | |
| D | 2023-10-30 | 2023-10-26 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 421.8K | +0.7% | +$3,180 |
| D | 2023-10-30 | 2023-10-26 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $5.63 | -3,000 | 418.8K | -0.7% | -$16.9K |
| 2023-10-19 | 2023-10-17 | RXRX | Borgeson Blake | Dir | S - Sale | $6.58 | -8,885 | 7.43M | -0.1% | -$58.5K | |
| D | 2023-10-18 | 2023-10-16 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 158.4K | +13% | +$40.0K |
| D | 2023-10-18 | 2023-10-16 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $6.30 | -18.0K | 140.4K | -11% | -$113.4K |
| D | 2023-10-18 | 2023-10-16 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 842.7K | -1% | $0 |
| D | 2023-10-18 | 2023-10-16 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 852.7K | +1% | $0 |
| DM | 2023-10-12 | 2023-10-10+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 938.2K | +9% | +$166.5K |
| DM | 2023-10-12 | 2023-10-10+ | RXRX | Secora Michael | CFO | S - Sale+OE | $6.96 | -50.0K | 900.7K | -5% | -$348.0K |
| D | 2023-10-06 | 2023-10-04 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 902.5K | +4% | +$77.5K |
| D | 2023-10-06 | 2023-10-04 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $7.21 | -59.8K | 842.7K | -7% | -$431.1K |
| 2023-10-05 | 2023-10-03 | RXRX | Borgeson Blake | Dir | S - Sale | $7.29 | -8,885 | 7.43M | -0.1% | -$64.8K | |
| 2023-10-04 | 2023-10-02 | RXRX | Li Dean Y | Dir | A - Grant | $0.00 | +1,659 | 1.33M | +0.1% | $0 | |
| I | 2023-10-04 | 2023-04-21 | RXRX | Li Dean Y | Dir | G - Gift | $0.00 | -627.7K | 0 | -100% | $0 |
| 2023-10-04 | 2023-10-02 | RXRX | CHAVEZ R. MARTIN | Dir | A - Grant | $0.00 | +2,619 | 56.2K | +5% | $0 | |
| 2023-10-04 | 2023-10-02 | RXRX | Dar Zavain | Dir | A - Grant | $0.00 | +1,920 | 74.0K | +3% | $0 | |
| D | 2023-10-02 | 2023-09-28 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $7.72 | -3,000 | 418.8K | -0.7% | -$23.2K |
| D | 2023-10-02 | 2023-09-28 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 421.8K | +0.7% | +$3,180 |
| 2023-09-21 | 2023-09-19 | RXRX | Borgeson Blake | Dir | S - Sale | $8.36 | -8,885 | 7.44M | -0.1% | -$74.3K | |
| D | 2023-09-19 | 2023-09-15 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 881.3K | +1% | $0 |
| D | 2023-09-19 | 2023-09-15 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 871.3K | -1% | $0 |
| D | 2023-09-19 | 2023-09-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 158.4K | +13% | +$40.0K |
| D | 2023-09-19 | 2023-09-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $8.66 | -18.0K | 140.4K | -11% | -$155.9K |
| DM | 2023-09-14 | 2023-09-12+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 913.2K | +9% | +$166.5K |
| DM | 2023-09-14 | 2023-09-12+ | RXRX | Secora Michael | CFO | S - Sale+OE | $8.56 | -50.0K | 888.2K | -5% | -$428.0K |
| DMI | 2023-09-08 | 2023-09-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.83 | -25.0K | 0 | -100% | -$220.8K |
| DMI | 2023-09-08 | 2023-09-06 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +25.0K | 1,000 | New | $0 |
| D | 2023-09-08 | 2023-09-06 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $2.48 | +31.2K | 905.1K | +4% | +$77.5K |
| D | 2023-09-08 | 2023-09-06 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $8.78 | -33.8K | 871.3K | -4% | -$296.5K |
| 2023-09-07 | 2023-09-05 | RXRX | Borgeson Blake | Dir | S - Sale | $8.79 | -8,885 | 7.45M | -0.1% | -$78.1K | |
| DM | 2023-08-28 | 2023-08-24 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $8.66 | -3,000 | 418.8K | -0.7% | -$26.0K |
| D | 2023-08-28 | 2023-08-24 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +3,000 | 421.8K | +0.7% | +$3,180 |
| 2023-08-24 | 2023-08-22 | RXRX | Borgeson Blake | Dir | S - Sale | $8.91 | -8,885 | 7.46M | -0.1% | -$79.2K | |
| 2023-08-17 | 2023-08-15 | RXRX | Larson Tina Marriott | Pres, COO | F - Tax | $9.18 | -5,378 | 418.8K | -1% | -$49.4K | |
| D | 2023-08-17 | 2023-08-15 | RXRX | Virani Shafique | Chief Business Off | F - Tax | $9.19 | -3,603 | 140.4K | -3% | -$33.1K |
| D | 2023-08-17 | 2023-08-15 | RXRX | Virani Shafique | Chief Business Off | S - Sale+OE | $9.25 | -18.0K | 140.4K | -11% | -$166.5K |
| D | 2023-08-17 | 2023-08-15 | RXRX | Virani Shafique | Chief Business Off | M - OptEx | $2.22 | +18.0K | 158.4K | +13% | +$40.0K |
| 2023-08-17 | 2023-08-15 | RXRX | Gibson Christopher | CEO, Dir | F - Tax | $9.19 | -16.9K | 873.8K | -2% | -$155.4K | |
| DM | 2023-08-17 | 2023-08-15+ | RXRX | Secora Michael | CFO | M - OptEx | $2.22 | +75.0K | 875.7K | +9% | +$166.5K |
| DM | 2023-08-17 | 2023-08-15+ | RXRX | Secora Michael | CFO | S - Sale+OE | $9.09 | -50.0K | 850.7K | -6% | -$454.3K |
| D | 2023-08-17 | 2023-08-15 | RXRX | Secora Michael | CFO | F - Tax | $9.19 | -4,727 | 838.2K | -0.6% | -$43.4K |
| D | 2023-08-11 | 2023-08-09 | RXRX | Gibson Christopher | CEO, Dir | G - Gift | $0.00 | -10.0K | 890.7K | -1% | $0 |
| D | 2023-08-11 | 2023-08-09 | RXRX | Gibson Christopher | CEO, Dir | C - Cnv Deriv | $0.00 | +10.0K | 900.7K | +1% | $0 |
| M | 2023-08-10 | 2023-08-08 | RXRX | Borgeson Blake | Dir | S - Sale | $11.16 | -17.8K | 7.47M | -0.2% | -$198.4K |
| DM | 2023-08-04 | 2023-08-02 | RXRX | Gibson Christopher | CEO, Dir | M - OptEx | $4.42 | +39.9K | 955.7K | +4% | +$176.4K |
| DM | 2023-08-04 | 2023-08-02 | RXRX | Gibson Christopher | CEO, Dir | S - Sale+OE | $13.04 | -65.0K | 894.8K | -7% | -$847.9K |
| DM | 2023-07-28 | 2023-07-27 | RXRX | Larson Tina Marriott | Pres, COO | S - Sale+OE | $13.63 | -8,000 | 424.2K | -2% | -$109.0K |
| D | 2023-07-28 | 2023-07-27 | RXRX | Larson Tina Marriott | Pres, COO | M - OptEx | $1.06 | +8,000 | 432.2K | +2% | +$8,480 |
| 2023-07-27 | 2023-06-29 | RXRX | Borgeson Blake | Dir | G - Gift | $0.00 | -14.0K | 7.51M | -0.2% | $0 | |
| 2023-07-27 | 2023-07-25 | RXRX | Borgeson Blake | Dir | S - Sale | $14.61 | -18.7K | 7.49M | -0.2% | -$273.5K |
Purchase Sale Sale after option exercise All abbreviations